Dynamics of SARS-CoV-2 VOC neutralization and novel mAb reveal protection against Omicron
Authors:
Preprint
Abstract
To evaluate SARS-CoV-2 variants we isolated SARS-CoV-2 temporally during the pandemic starting with first appearance of virus in the Western hemisphere near Seattle, WA, USA, and isolated each known major variant class, revealing the dynamics of emergence and complete take-over of all new cases by current Omicron variants. We assessed virus neutralization in a first-ever full comparison across variants and evaluated a novel monoclonal antibody (Mab). We found that convalescence greater than 5-months provides little-to-no protection against SARS-CoV-2 variants, vaccination enhances immunity against variants with the exception of Omicron BA.1, and paired testing of vaccine sera against ancestral virus compared to Omicron BA.1 shows that 3-dose vaccine regimen provides over 50-fold enhanced protection against Omicron BA.1 compared to a 2-dose regimen. We also reveal a novel Mab that effectively neutralizes Omicron BA.1 and BA.2 variants over clinically-approved Mabs. Our observations underscore the need for continued vaccination efforts, with innovation for vaccine and Mab improvement, for protection against variants of SARS-CoV-2. Summary We isolated SARS-CoV-2 temporally starting with emergence of virus in the Western hemisphere. Neutralization analyses across all variant lineages show that vaccine-boost regimen provides protection against Omicron BA.1. We reveal a Mab that protects against Omicron BA.1 and BA.2 variants.Keywords
All Related Versions
- Published version: Viruses, 15 (2), 530.
This publication has 47 references indexed in Scilit:
- REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19New England Journal of Medicine, 2021
- Sensitive Recovery of Complete SARS-CoV-2 Genomes from Clinical Samples by Use of Swift Biosciences’ SARS-CoV-2 Multiplex Amplicon Sequencing PanelJournal of Clinical Microbiology, 2020
- An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19bioRxiv, 2020
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trialTrials, 2020
- Broad neutralization of SARS-related viruses by human monoclonal antibodiesScience, 2020
- Comparison of Commercially Available and Laboratory-Developed Assays for In Vitro Detection of SARS-CoV-2 in Clinical LaboratoriesJournal of Clinical Microbiology, 2020
- A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiologyNature Microbiology, 2020
- MEGA X: Molecular Evolutionary Genetics Analysis across Computing PlatformsMolecular Biology and Evolution, 2018
- A SARS-like cluster of circulating bat coronaviruses shows potential for human emergenceNature Medicine, 2015
- aLeaves facilitates on-demand exploration of metazoan gene family trees on MAFFT sequence alignment server with enhanced interactivityNucleic Acids Research, 2013